AI-powered drug discovery platform using generative biology
Generate:Biomedicines applies machine learning (PyTorch, JAX, TensorFlow) to protein design and therapeutic discovery. The tech stack—spanning analytical chemistry (HPLC, LC-MS), cloud infrastructure (GCP, AWS, Azure), and ML frameworks—reveals a wet-lab-meets-AI model. Hiring velocity is accelerating across research and leadership roles, with active efforts to scale high-throughput screening, biosensor integration, and clinical data infrastructure; pain points around sample-volume reduction and assay scaling suggest the platform is moving from bench science toward automated, AI-driven optimization.
Notable leadership hires: Therapeutic Applications Lead, Project Team Lead
Generate:Biomedicines develops a generative biology platform to design and validate therapeutic candidates. The company operates across preclinical and clinical stages, with active programs in late-stage asthma development and early-stage therapeutic discovery enabled by AI-designed molecules. Operations span analytical chemistry, bioinformatics, clinical monitoring, and investor relations—typical of a growth-stage biotech moving from R&D-focused to revenue-generating. Based in Somerville, Massachusetts, the company employs 201–500 people and is privately held.
PyTorch, JAX, and TensorFlow are in active use, alongside NumPy and SciPy for scientific computing. These support protein design and AI-driven drug discovery workflows.
The company uses GCP, AWS, and Azure. AWS infrastructure includes Redshift, ECS, Kubernetes, and Argo CD for orchestration and data warehousing.
Generate:Biomedicines's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.